Clinical trial
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
NCT00383708 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00383708 |
|---|---|
| Title | Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients |
| Official title | Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in… |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | lanreotide (Autogel formulation), Pegvisomant |
| Enrollment | 125 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Oct 3, 2006 |
| Last update posted | Sep 27, 2022 |
| Countries | Czechia, Denmark, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: